Journal
ACS CHEMICAL NEUROSCIENCE
Volume 10, Issue 1, Pages 143-154Publisher
AMER CHEMICAL SOC
DOI: 10.1021/acschemneuro.8b00433
Keywords
Hallucinogens; antimuscarinic agents; deliriants; zebrafish; rodents
Funding
- Russian Foundation for Basic Research (RFBR) [16-04-00851]
Ask authors/readers for more resources
Hallucinogenic drugs potently alter human behavior and have a millennia-long history of use for medicinal and religious purposes. Interest is rapidly growing in their potential as CNS modulators and therapeutic agents for brain conditions. Antimuscarinic cholinergic drugs, such as atropine and scopolamine, induce characteristic hyperactivity and dream-like hallucinations and form a separate group of hallucinogens known as deliriants. Although atropine and scopolamine are relatively well-studied drugs in cholinergic physiology, deliriants represent the least-studied class of hallucinogens in terms of their behavioral and neurological phenotypes. As such, novel approaches and new model organisms are needed to investigate the CNS effects of these compounds. Here, we comprehensively evaluate the preclinical effects of deliriant hallucinogens in various animal models, their mechanisms of action, and potential interplay with other signaling pathways. We also parallel experimental and clinical findings on deliriant agents and outline future directions of translational research in this field.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available